Vilin Bio Med IPO GMP, Review, Price, Allotment
The pharmaceutical industry has been witnessing significant growth over the years, driven by the increasing demand for healthcare products and services. Vilin Bio Med, a company incorporated in 2005, has emerged as a key player in the domestic pharmaceutical manufacturing sector. In this article, we will delve into the details of Vilin Bio Med’s Initial Public Offering (IPO), including its description, IPO details, financial performance, valuations, and the IPO’s GMP (Grey Market Premium) and listing performance.
Introduction
Vilin Bio Med, based in Roorkee, Uttarakhand, is actively involved in the manufacturing of pharmaceutical products. With a dedicated manufacturing unit and a strong research and development foundation, the company strives to enhance healthcare and maintain its competitive edge in the industry. By expanding its production capacity and capitalizing on economies of scale, Vilin Bio Med aims to reduce operational costs and increase its profit margins.
Vilin Bio Med IPO Description
Vilin Bio Med’s IPO marks its entry into the capital market to raise funds for further growth and expansion. The company plans to offer 40,00,000 shares at a price of INR 30 per share. The IPO will be open for subscription from 16th to 21st June 2023. The face value of each share is INR 10, and the minimum bid (lot size) is set at 4,000 shares (INR 120,000). Retail investors have been allocated a 50% portion of the IPO.
Vilin Bio Med IPO Details
- IPO Dates: 16th – 21st June 2023
- IPO Price: INR 30 per share
- Fresh Issue: 40,00,000 shares (INR 12.0 crores)
- Offer For Sale: NIL
- Total IPO Size: 40,00,000 shares (INR 12.0 crores)
- Minimum Bid (Lot Size): 4,000 shares (INR 120,000)
- Face Value: INR 10 per share
- Retail Allocation: 50%
- Listing On: NSE SME
Vilin Bio Med Financial Performance
Let’s take a look at Vilin Bio Med’s financial performance over the past few years:
| FY 2020 | FY 2021 | FY 2022 | 9M FY 2023 | |
|---|---|---|---|---|
| Revenue | 1,681.29 | 1,171.52 | 1,121.49 | 901.29 |
| Expenses | 1,663.03 | 1,155.77 | 1,117.44 | 728.98 |
| Net Income | 16.22 | 12.13 | 3.35 | 128.08 |
Figures in INR Lakhs unless specified otherwise
Vilin Bio Med has shown consistent revenue growth over the years. Although there was a slight decline in revenue from FY 2020 to FY 2021, the company managed to recover in FY 2022 and the first nine months of FY 2023. However, it’s important to note that the net income has been fluctuating during this period.
Vilin Bio Med Valuations & Margins
Here are some key valuation and margin metrics for Vilin Bio Med:
| FY 2020 | FY 2021 | FY 2022 | |
|---|---|---|---|
| EPS | 0.20 | 0.15 | 0.04 |
| PE Ratio | – | – | 275.00 |
| RONW (%) | 2.24 | 1.65 | 0.45 |
| NAV | 8.78 | 8.92 | 8.96 |
| ROCE (%) | 1.37 | 0.94 | 0.26 |
| EBITDA (%) | 5.41 | 7.34 | 6.86 |
*Compiled by IPO Central from Prospectus
The earnings per share (EPS) of Vilin Bio Med has been gradually decreasing from FY 2020 to FY 2022, indicating a potential decline in profitability. The price-to-earnings (PE) ratio is not available for the mentioned years. Return on net worth (RONW) has also witnessed a downward trend, which might be a cause for concern.
Vilin Bio Med IPO GMP Today
The Grey Market Premium (GMP) for Vilin Bio Med’s IPO will be available closer to the IPO opening date. GMP is an unofficial market where IPO shares are traded before their official listing. It provides an indication of investor sentiment and demand for the IPO. Investors should keep an eye on GMP updates to make informed decisions regarding Vilin Bio Med’s IPO.
Vilin Bio Med IPO Dates & Listing Performance
The IPO timeline and listing performance are as follows:
- IPO Opening Date: 16th June 2023
- IPO Closing Date: 21st June 2023
- Finalization of Basis of Allotment: 26th June 2023
- Initiation of Refunds: 27th June 2023
- Transfer of Shares to Demat Accounts: 29th June 2023
- IPO Listing Date: 30th June 2023
- Opening Price on NSE SME: Coming soon
- Closing Price on NSE SME: Coming soon
Investors can anticipate the opening and closing prices of Vilin Bio Med’s shares on the NSE SME exchange once the IPO is listed. These prices will reflect the market’s response to the company’s IPO and its future prospects.
Conclusion
Vilin Bio Med’s IPO presents an opportunity for investors to participate in the growth of the pharmaceutical sector. The company’s focus on research and development, along with its plans to scale up production and leverage economies of scale, positions it for potential success. However, investors should carefully evaluate the company’s financial performance, valuations, and market conditions before making investment decisions.
FAQs
How often does the IPO Grey Market Premium change?
The Grey Market Premium is dynamic and can change frequently, influenced by market conditions and investor sentiment. It is advisable to stay updated with the latest figures through reliable sources.
Can investors participate in the Grey Market trading?
Grey Market trading is conducted through a network of dealers, and participation is limited to select individuals or entities. It is an unofficial market and not regulated like the stock exchange.
Should investors rely solely on the IPO Grey Market Premium for investment decisions?
No, investors should consider the Grey Market Premium as one of several factors when making investment decisions. Thorough research, analysis of company fundamentals, and expert advice are equally important.
What is the significance of Kostak rates in IPO investments?
Kostak rates represent the price at which investors can sell their IPO application before listing. It provides an opportunity for early exits. Investors should evaluate both GMP and Kostak rates to make informed decisions.
Disclaimer:
The information provided in this article is for informational purposes only and should not be construed as investment advice. Investors are advised to conduct their own research and consult with financial professionals before making any investment decisions.
